登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C22H28O2
化学文摘社编号:
分子量:
324.46
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
EC Number:
258-936-2
MDL number:
color
white to beige
InChI
1S/C22H28O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,17-20,24H,3-4,6-11,13H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1
InChI key
GCKFUYQCUCGESZ-BPIQYHPVSA-N
SMILES string
CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D +80 to +95°, c = 1 (CHCl3)
solubility
DMSO: >5 mg/mL
storage temp.
−20°C
Quality Level
Gene Information
human ... PGR(5241)
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
Etonogestrel is a lipophilic molecule. Pharmacokinetics studies reveal that etonogestrel is bound to protein albumin in the blood. This remains independent of both endogenous and exogenous concentration of estradiol.
Etonogestrel is a progestin, contraceptive.
Etonogestrel is a third-generation progestin contraceptive. Etonogestrel is used as a contraceptive itself and is also the active metabolite of the drug desogestrel used in some combination contraceptives.
Features and Benefits
This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
signalword
Danger
hcodes
pcodes
Hazard Classifications
Carc. 2 - Repr. 1B
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Anne Calhoun et al.
Headache, 52(8), 1246-1253 (2012-07-14)
To determine whether extended-cycle dosing of an ultralow dose vaginal ring contraceptive decreases frequency of migraine aura and prevents menstrual related migraine (MRM). Many women are denied therapy with combined hormonal contraceptives due to published guidelines that recommend against their
Diana Mansour et al.
Contraception, 83(3), 202-210 (2011-02-12)
The aim of this guidance is to review the management of unacceptable vaginal bleeding patterns in etonogestrel (ENG)-releasing contraceptive implant users concentrating, where possible, on the evidence for pharmacological treatments and identifying a pragmatic approach where this is not possible.
Peter Schnabel et al.
Clinical drug investigation, 32(6), 413-422 (2012-05-01)
The etonogestrel (ENG)-releasing implant is a subdermal progestogen-only contraceptive that provides coverage for up to 3 years. This long-acting hormonal contraceptive has been available in Europe since 1998 and in the US since 2006. To date, localization of non-palpable implants
Kristina M Tocce et al.
American journal of obstetrics and gynecology, 206(6), 481-481 (2012-05-29)
The purpose of this study was to determine contraceptive continuation and repeat pregnancy rates in adolescents who are offered immediate postpartum etonogestrel implant (IPI) insertion. Participants in an adolescent prenatal-postnatal program were enrolled in a prospective observational study of IPI
Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon
Wenzl R, et al.
Contraception, 58(5), 283-288 (1998)
商品
We offers many products related to Nuclear Receptors (Steroids) for your research needs.
我们可提供多种核受体(类固醇)相关产品,满足您的各类研究需求。
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持